title: Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers.
abstract: The authors examined the effect of the cyclooxygenase-2 (COX-2) inhibitor, rofecoxib, at steady state on the pharmacokinetics of digoxin following a single dose in healthy subjects. Each healthy subject (N = 10) received rofecoxib (75 mg once daily) or placebo for 11 days in a double-blind, randomized, balanced, two-period crossover study. A single 0.5 mg oral dose of digoxin elixir was administered on the 7th day of each 11-day period. Each treatment period was separated by 14 to 21 days. Samples for plasma and urine immunoreactive digoxin concentrations were collected through 120 hours following the digoxin dose. No statistically significant differences between treatment groups were observed for any of the calculated digoxin pharmacokinetic parameters. For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. The digoxin median tmax was 0.5 hours for both treatments. The harmonic mean elimination half-life was 45.7 and 43.4 hours for rofecoxib + digoxin and placebo + digoxin treatments, respectively. Digoxin is eliminated renally. The mean (SD) cumulative urinary excretion of immunoreactive digoxin after concurrent treatment with rofecoxib or placebo was 228.2 (+/- 30.8) and 235.1 (+/- 39.1) micrograms/120 hours, respectively. Transient and minor adverse events occurred with similar frequency on placebo and rofecoxib treatments, and no treatment-related pattern was apparent. Rofecoxib did not influence the plasma pharmacokinetics or renal elimination of a single oral dose of digoxin.
authors.affiliation: Merck Research Laboratories, Rahway, New Jersey, USA.
authors.forename: J I
authors.initials: JI
authors.lastname: Schwartz
authors.forename: M
authors.initials: M
authors.lastname: De Smet
authors.forename: P J
authors.initials: PJ
authors.lastname: Larson
authors.forename: R
authors.initials: R
authors.lastname: Verbesselt
authors.forename: D L
authors.initials: DL
authors.lastname: Ebel
authors.forename: R
authors.initials: R
authors.lastname: Lins
authors.forename: S
authors.initials: S
authors.lastname: Lens
authors.forename: A G
authors.initials: AG
authors.lastname: Porras
authors.forename: B J
authors.initials: BJ
authors.lastname: Gertz
mesh_terms: D000284:Administration, Oral; D000328:Adult; D002316:Cardiotonic Agents / Q000097:blood / Q000494:pharmacology* / Q000652:urine; D018592:Cross-Over Studies; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D004077:Digoxin / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D004311:Double-Blind Method; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007783:Lactones / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D013450:Sulfones
chemical_list: D002316:Cardiotonic Agents; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib; D004077:Digoxin